Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» migraines
migraines
Biohaven scores CGRP OK for acute migraine — can the commercial team catch up with Allergan on its debut?
Endpoints
Thu, 02/27/20 - 11:46 pm
Biohaven
FDA
migraines
Nurtec
Allergan
AbbVie
Ubrelvy
In final report, ICER appears to have a change of heart on new acute migraine therapies
Endpoints
Tue, 02/25/20 - 10:40 am
ICER
migraines
Biohaven
Allergan
ubrogepant
rimegepant
Eli Lilly
Lasmiditan
The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B
Endpoints
Sat, 02/22/20 - 11:29 pm
Lundbeck
eptinezumab
migraines
CGRPs
Vyepti
Allergan's Botox still a physician favorite for migraine despite CGRP push: analyst
Fierce Pharma
Fri, 02/21/20 - 10:49 am
Allergan
Botox
migraines
physicians
neurologists
CGRPs
Saniona Co-Founds New Migraine-Focused Company
BioSpace
Tue, 02/18/20 - 08:33 pm
Saniona
migraines
Denmark
Cephagenix
Lilly's migraine reliever Reyvow cleared for launch, beating Allergan's rival Ubrelvy to market
Fierce Pharma
Fri, 01/31/20 - 12:14 pm
migraines
Eli Lilly
Reyvow
Allergan
Ubrelvy
Teva's Ajovy finally gets its autoinjector nod. Can it close the gap with Amgen, Lilly meds?
Fierce Pharma
Wed, 01/29/20 - 10:45 am
Teva Pharmaceutical
Ajovy
migraines
autoinjectors
FDA
CGRPs
Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter
Fierce Pharma
Fri, 01/3/20 - 11:03 pm
FDA
migraines
cholesterol
Epizyme
tazemetostat
Esperion
bempedoic acid
teprotumumab
Horizon Therapeutics
Biohaven
rimegepant
Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launch
Fierce Pharma
Mon, 12/23/19 - 11:56 pm
Allergan
UIbrelvy
ubrogepant
FDA
migraines
CGRPs
Lilly launches real-world study to benchmark Emgality against migraine rivals
Fierce Pharma
Wed, 12/18/19 - 11:54 pm
Eli Lilly
migraines
Emgality
real world evidence
RWE
3 Biotechs Facing FDA Approvals by Year's End
Motley Fool
Mon, 12/9/19 - 09:45 am
FDA
Amgen
Vascepa
Allergan
migraines
ubrogepant
Intra-Cellular Therapies
lumateperone
schizophrenia
Go or no go? Vascepa’s finale and Allergan's pain relief
EP Vantage
Mon, 12/2/19 - 10:37 am
FDA
Amarin
Vascepa
Allergan
migraines
ubrogepant
Before 2019 closes, the FDA has 3 key approval decisions to make
Biopharma Dive
Wed, 11/27/19 - 12:43 pm
Allergan
ubrogepant
migraines
Amarin
Vascepa
Intra-Cellular Therapeutics
lumateperone
schizophrenia
bipolar disorder
drug approvals
FDA
Allergan builds case for migraine drug ubrogepant as FDA verdict nears
Pharmaforum
Wed, 11/20/19 - 10:04 am
Allergan
migraines
ubrogepant
FDA
Upcoming events – Axsome takes on migraine and Kala looks to dry eye again
EP Vantage
Sun, 11/10/19 - 07:58 pm
Axsome Therapeutics
migraines
AXS-07
Kala Pharmaceuticals
clinical trials
KP-121
dry eye disease
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
Xconomy
Fri, 10/11/19 - 10:50 pm
Eli Lilly
migraines
Lasmiditan
FDA
Reyvow
Blow to Novartis as NICE rejects migraine drug Aimovig again
Pharmaforum
Thu, 09/26/19 - 10:54 am
Novartis
Aimovig
migraines
NICE
Alder won’t solve Lundbeck’s headaches
EP Vantage
Mon, 09/16/19 - 05:12 pm
Lundbeck
M&A
Alder Biopharmaceuticals
migraines
Amgen's Aimovig, under fire from Lilly, loses grip on CGRP share
Fierce Pharma
Thu, 09/5/19 - 10:37 am
Amgen
CGRPs
Aimovig
migraines
Eli Lilly
Emgality
Teva’s CGRP-Inhibitor Reduced Monthly Migraine Days in Late-Stage Trial
BioSpace
Thu, 08/22/19 - 11:06 am
migraines
Teva Pharmaceutical
CGRP blockers
clinical trials
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »